热疗、介入联合索拉非尼治疗原发性肝癌的研究

目的探讨使用索拉非尼基础上联合热疗、介入治疗原发性肝癌的临床效果及安全性。方法选取原发性肝癌患者49例,随机分为观察组与对照组,对照组给予介入联合局部热疗治疗,观察组在对照组基础上联合索拉非尼治疗,对比观察2组临床疗效及不良反应情况。结果观察组治疗有效率及获益率均明显高于对照组(P均0.05);治疗后观察组卡氏评分明显升高(P0.05),且显著高于对照组(P0.05);2组治疗期间胃肠道反应、白细胞计数降低、肝功损伤等不良反应发生率差异无统计学意义(P0.05)。结论热疗、介入联合索拉非尼治疗原发性肝癌,能够有效改善患者临床症状,控制病情恶化,明显提高其生活质量,且不会增加不良反应,安全性较好,具有良好的临床应用效果及推广价值。

Research on thermal therapy,intervention combined with Sorafenib in treatment of primary liver cancer

Objective It is to approach the clinical effect and safety of thermal therapy, intervention combined with Sor- afenib in treatment of primary liver cancer. Methods 49 cases with primary liver cancer were selected and divided into the ob- servation group and the control group randomly. The patients were treated with intervention combined with local thermal thera- py in control group, and with Sorafenib based on the treatment of control group in observation group. The clinical effect and adverse reactions of two groups were compared. Results The effective rate and the benefit rate of the observation group was evi- dently higher than that of the control group （ all P 〈 0.05）. After treatment, the Karnofsky score of the observation group was increased evidently, and was higher than that of the control group （ P 〈 0.05 ）. There was no significant difference in the inci- dence rate of adverse reactions including gastrointestinal reaction, white blood cell count reduction and liver function damage between two groups （P 〉 0.05）. Conclusion Thermal therapy, intervention combined with Sorafcnib in treatment of primary liver cancer not only can effectively improve clinical symptoms, control the disease and evidently improve the life quality of pa- tients, but also can＇ t increase adverse reactions and is safe, which has great clinical application effect and promotion value.